Description: Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for the management of moderate to moderately severe postoperative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Tramadol is also combined with acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDS) in clinical practice. During the year ending December 31, 2016, the Company had completed a pharmacokinetics (PK) study for IV Tramadol in healthy volunteers.
Home Page: www.avenuetx.com
ATXI Technical Analysis
1140 Avenue of the America
New York,
NY
10036
United States
Phone:
781 652 4500
Officers
| Name | Title |
|---|---|
| Dr. Lindsay Allan Rosenwald | Exec. Chairman |
| Dr. Xiaoqin Lu M.D. | Consultant |
| Dr. Alexandra MacLean M.D. | Chief Exec. Officer |
| Mr. David Jin | Interim CFO, COO & Corp. Sec. |
| Dr. Scott A. Reines M.D., Ph.D. | Interim Chief Medical Officer |
| Srinivas Subramanian | Exec. VP |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 17.9856 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 14.288 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2017-06-27 |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |